Scienture Holdings, Inc. — Filing identity note
The supplied filing is a Form 10-Q for Trxade Group, Inc., not Scienture Holdings, Inc. It covers the quarter and nine months ended September 30, 2019; financial statements are unaudited.
Business context and reporting period
Trxade operated a pharmaceutical marketplace and, through subsidiaries, pharmaceutical wholesale and retail pharmacy businesses. Community Specialty Pharmacy was acquired in October 2018; Integra and the pharmacy businesses contributed to the expanded operations reported in 2019.
Financial performance and position
| Metric | Three months ended Sept. 30 | Nine months ended Sept. 30 |
|---|---|---|
| Revenue, 2019 | $2.31 million | $5.74 million |
| Revenue, 2018 | $0.85 million | $2.54 million |
| Gross profit, 2019 | $1.31 million | $3.62 million |
| Operating income, 2019 | $177,853 | $482,317 |
| Net income, 2019 | $27,565 | $210,775 |
| Net income, 2018 | $94,249 | $197,031 |
- Revenue increased about 173% in Q3 and 126% for the nine-month period. Management attributed the growth primarily to the pharmacy and wholesaler businesses added since the comparable 2018 period.
- Gross margin was about 57% in Q3 2019 and 63% for the nine months, versus nearly 100% in 2018. The comparison is affected by the expanded product-selling businesses and 2018 cost of sales of only $2,345.
- Q3 net income declined about 71% year over year, despite higher revenue, reflecting higher operating costs and a $162,178 SyncHealth investment loss. Nine-month net income rose about 7%.
- Nine-month operating cash flow was $324,565, compared with $231,315 in 2018. Investing cash use was $250,000 for SyncHealth; financing cash provided was $2.42 million, mainly from stock issuance. Cash increased by $2.49 million to $3.36 million.
- At September 30, current assets were $4.31 million and current liabilities $955,685, including $322,552 of short-term related-party debt. Working capital was $3.36 million. Total liabilities were $1.96 million; related-party notes totaled $622,552 and lease liabilities $792,339.
- Stockholders’ equity was $3.89 million, up from $844,668 at year-end 2018. Common shares outstanding increased from 33.29 million to 38.64 million; 4.91 million shares were issued for $2.455 million during the period.
Changes, outlook, and risks
- SyncHealth, in which the company invested $250,000 for an equity interest, was fully impaired to zero. The company reported no income from its technology and said it was discussing dissolution of the relationship. Potential share issuances tied to revenue or EBITDA quotas could cause substantial dilution; the filing said no quotas had been achieved as of September 30.
- Management estimated general and administrative and working-capital needs of approximately $3.5 million for the following 12 months, and said additional financing may be needed. It cautioned that financing may not be available on favorable terms, or at all, and operations may not generate significant positive cash flow. No revenue or earnings guidance was provided.
- After quarter-end, the company repaid $222,552 of related-party notes and converted $175,000 of note principal into 350,000 shares. It also acquired specified telehealth assets on October 23 for 250,000 shares, with up to 650,000 additional milestone shares and a funding obligation of up to $600,000, subject to milestones.
- Management concluded disclosure controls and procedures were ineffective and disclosed an ongoing material weakness in internal control over financial reporting. Remediation was in progress and not complete.
- Disclosed risks include the need for external capital and potential dilution; pharmaceutical licensing and regulatory compliance; opioid-related litigation and regulation; cybersecurity and service interruptions; acquisition integration; and intellectual-property claims. The company reported no material change to previously disclosed risks except those identified in this filing.
- Related-party participation in financings and related-party borrowings are disclosed. The filing reported no off-balance-sheet arrangements and stated that ordinary-course legal matters were not expected to have a material adverse effect.
Investor verification priorities
- Confirm the issuer identity: this filing is for Trxade Group, Inc., despite the request naming Scienture Holdings, Inc.
- Review the material weakness, its cause, and the status and effectiveness of remediation.
- Assess the sustainability and margins of revenue growth, distinguishing marketplace fees from wholesale and pharmacy sales.
- Verify post-quarter related-party debt repayments and conversions, and the resulting share count and dilution.
- Evaluate the SyncHealth impairment, potential dissolution, and any contingent share obligations.
- Review the telehealth acquisition’s milestone shares, up-to-$600,000 funding commitment, and execution risks.
- Assess the $3.5 million estimated 12-month spending requirement against cash, operating cash flow, and the need for further financing.